PwPepwise

Pinealon

Anti-Aging & Longevity

Pineal-derived tripeptide

Pinealon is a synthetic tripeptide composed of three amino acids — glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg) — originally.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Human Studies100 mcgTwice dailyOralTaken by mouth.—
Animal Studies (Preclinical Reference Only)100 ng/kg—OralTaken by mouth.5 days
Summary100 mcgTwice dailyOralTaken by mouth.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Pinealon is a synthetic tripeptide composed of three amino acids — glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg) — originally developed in Russia as part of a broader program exploring short peptides with geroprotective and neuroprotective properties. It is named in reference to the pineal gland and is designed to support brain health, particularly under conditions of stress, aging, or metabolic disruption.

In preclinical research, pinealon has been reported to protect neurons from oxidative damage, reduce inflammation-related markers in the brain, and support cognitive function under challenging conditions such as hypoxia, hyperhomocysteinemia, and experimental diabetes1,2,3,4,5. It may help preserve spatial memory and learning ability, and early animal studies suggest it modulates neurotransmitter balance and supports cellular survival pathways3,9,12. In limited human studies, pinealon has been reported to improve biological age indicators and adaptive capacity in occupationally stressed workers10, and to support CNS function in patients with chronic neurological conditions6. A recent screening study in mice observed a trend toward improved working memory with no detected adverse effects over an 8-week period8. Research into pinealon's full range of applications is actively developing, with human evidence still emerging.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide consisting of glutamic acid, aspartic acid, and arginine in sequence. As an extremely short peptide, it is structurally capable of interacting directly with DNA regulatory elements, and multiple lines of evidence suggest its mechanisms extend beyond surface receptor engagement to include intranuclear activity.

At the cellular level, pinealon has been shown to suppress reactive oxygen species (ROS) accumulation across multiple cell types — including cerebellar granule cells, peripheral neutrophils, and dopaminergic PC12 cells — under both receptor-dependent and receptor-independent oxidative stress conditions2. This antioxidant activity saturates at lower peptide concentrations, while cell cycle modulation (including delayed ERK 1/2 activation and modified proliferative signaling) persists at higher concentrations2. This concentration-dependent dissociation of antioxidant and cell cycle effects has been interpreted as evidence of a direct genomic interaction distinct from membrane receptor signaling — a hypothesis consistent with the known behavior of short regulatory peptides described by Khavinson and colleagues.

In hippocampal tissue of streptozotocin-diabetic rats, pinealon has been reported to upregulate antioxidant enzyme genes including SOD1, GPX4, and GSR, shifting the hippocampal redox environment toward reduced free radical production15. In the same diabetic model, optimal spatial memory retention at 100 ng/kg was associated with the least deviation from control values in NMDA receptor subunit genes Grin1, Grin2b, and Grin2d, and with an increased Grin2a/Grin2b ratio3 — suggesting pinealon may modulate hippocampal NMDA receptor composition in a manner relevant to synaptic plasticity and memory consolidation under metabolic stress.

Neuroinflammatory pathway modulation has been observed in aged hypoxic rats, where pinealon appeared to normalize IL-6 and TNF-alpha levels toward reference values and was associated with evidence of neurogenesis5. Anti-apoptotic effects — measured as reductions in caspase-3 activity — were observed in neonatal brain tissue following prenatal pinealon exposure in hypoxia models4, though in a carotid occlusion paradigm, a paradoxical moderate elevation of caspase-3 activity was observed alongside improved survival7,13, indicating that pinealon's relationship with apoptotic cascades may be context- and brain-region-dependent.

At the neuroendocrine level, pinealon has been reported to correct disrupted diurnal norepinephrine dynamics in the hypothalamic medial preoptic area under hyperhomocysteinemia, implicating modulation of the norepinephrine-GnRH axis11. Additional neurochemical analyses in ischemic aged rats showed pinealon associated with upregulation of catecholaminergic mediators (DOPA, dopamine) in cerebral cortex post-occlusion14, and promotion of adrenergic and serotonergic mediator accumulation under hypoxia and hypothermia respectively9. Molecular marker studies suggest activation of proliferation-associated markers Ki67 and p53, alongside stimulation of serotonin, calmodulin, and melatonin synthesis in cortical neurons16, though these findings derive from low-quality publication venues. Formal pharmacokinetic characterization — including bioavailability, half-life, and metabolic fate — has not yet been reported in the accessible literature.

§04Evidence & efficacy

Evidence base
23Studies
4Human
4Animal

Pinealon's efficacy evidence base is grounded primarily in replicated preclinical findings across multiple animal models, with early and limited human data providing initial translational signals.

Neuroprotection under oxidative and metabolic stress: Pinealon has been reported to reduce reactive oxygen species accumulation and necrotic cell death in cerebellar granule cells, neutrophils, and PC12 cells under oxidative challenge, with effects observed across receptor-dependent and receptor-independent stress pathways2. In rat models of experimental diabetes, it may upregulate antioxidant enzyme gene expression (SOD1, GPX4, GSR) in hippocampal tissue and shift the pro-antioxidant balance favorably, with 100 ng/kg appearing more effective than 50 ng/kg3,15.

Cognitive function: In offspring of hyperhomocysteinemic pregnant rats, maternal pinealon administration was associated with improved spatial orientation and learning ability alongside reduced neuronal oxidative stress and necrosis1. In diabetic rats, spatial memory retention appeared best preserved at the 100 ng/kg dose, with an inverted U-shaped dose-response pattern and concurrent normalization of hippocampal NMDA receptor subunit gene expression3. Pinealon has been reported to outperform cortexin in navigation learning in both young and old rats under hypoxic conditions12, and showed a trend toward improved working memory in a recent mouse screening study8.

Neuroinflammation and apoptosis: Pinealon may reduce neuroinflammatory markers including IL-6 and TNF toward baseline levels in aged rats under hypoxic injury5, and has been associated with reduced caspase-3 apoptotic activity in brain structures of neonates exposed to prenatal hypoxia4. Paradoxically, in one carotid occlusion model, pinealon was associated with moderately increased caspase-3 activity despite improved survival, suggesting context-dependent apoptotic pathway interactions7,13.

Neuroendocrine modulation: Pinealon has been reported to correct hyperhomocysteinemia-induced disruptions of diurnal norepinephrine dynamics in the hypothalamic medial preoptic area of female rats, with implications for GnRH-mediated reproductive regulation11.

Human studies: In an uncontrolled study of locomotive brigade workers, two weeks of pinealon supplementation was associated with improvements in biological age parameters and adaptive capacity10. In patients with chronic polymorbidity and organic brain syndrome, pinealon demonstrated reported anabolic and neuroprotective effects, though Vesugen showed superior geroprophylactic outcomes in the same study6.

§05Safety

Pinealon's safety profile is based on limited preclinical data and a small number of uncontrolled human studies, with formal human safety trials not yet published.

In animal studies, pinealon was generally well-tolerated. Prenatal administration to pregnant rats across multiple models produced no reported maternal toxicity and was associated with improved neonatal outcomes1,4. A recent 8-week mouse screening study reported no detectable adverse effects, including no hematological or urinary abnormalities, in contrast to several comparator compounds in the same study which exhibited clear safety signals8.

However, some preclinical findings introduce biological complexity. In aged rats subjected to carotid artery occlusion, pinealon was associated with a moderate increase in caspase-3 activity in both sham-operated and occluded animals7,13 — a marker of apoptotic signaling — despite an observed survival benefit, suggesting the relationship between pinealon and apoptotic pathways is not straightforwardly neuroprotective across all contexts.

In the one human study reporting safety-relevant data, prooxidant activity was detected via chemiluminescence following peptide administration, alongside a decrease in CD34+ hematopoietic stem cells indicating suppression of hematopoiesis6. These signals were observed in a small, uncontrolled cohort, and their clinical significance is being investigated as human research continues.

No drug interactions or contraindications have been formally characterized in the available literature.

§06History

Pinealon (Glu-Asp-Arg) was developed as part of a long-running Russian peptide bioregulator research program pioneered by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the 1970s and accelerating through the 1990s and 2000s. This program produced a family of short di- to tetrapeptides designed to mimic regulatory sequences from organ-specific tissues, with the goal of restoring organ function during aging or disease. Pinealon was designed to target brain tissue, with its name evoking an association with the pineal gland, a key regulator of circadian biology and melatonin synthesis.

Early mechanistic work established that pinealon reduces ROS accumulation and necrotic cell death across multiple neuronal and immune cell types, with evidence of direct cell cycle modulation distinct from antioxidant activity alone2. Subsequent animal research expanded into models of prenatal hyperhomocysteinemia1, prenatal hypoxia4, carotid artery occlusion in aged rats7,13, and experimental diabetes3,15, collectively building a preclinical profile centered on neuroprotection and cognitive preservation across diverse stressor paradigms.

Human research has been limited and largely uncontrolled, with studies in occupationally stressed workers10 and patients with organic brain syndrome6 published primarily in Russian-language gerontology journals in the 2010s. By the mid-2020s, pinealon attracted international preclinical attention, appearing in a decentralized science (DeSci)-funded mouse longevity screening study8. It is currently commercially available as a research peptide, and its evidence base continues to develop across neuroprotective and geroprotective research contexts.

§07References